Novartis AG (NVS) Price Target Analysis
Wall Street analyst price targets, ratings consensus & upside potential · Updated May 1, 2026
Current Price
$148.36
Price Target
$141.00
Target Range
$112.00 — $170.00
Analyst Rating
Hold
Forward P/E16.9x
Trailing P/E20.6x
Forward PEG1.10
Implied Growth+24.1%
Median Target$141.00
Analyst Spread41.1%
Price Forecast (1 Year)
Last 12 months price action with 12-month analyst target path
Bear Case
$112
-24.5%
Consensus
$141
-5.0%
Bull Case
$170
+14.6%
Valuation Model TargetsConfidence: 56/100
Bear$127
Base$168
Bull$326
NVS Price Target Analysis
Updated May 7, 2026As of May 7, 2026, Novartis AG (NVS) has a Wall Street consensus price target of $141.00, based on estimates from 25 covering analysts. With the stock currently trading at $148.36, this represents a potential downside of -5.0%. The company has a market capitalization of $283.08B.
Analyst price targets range from a low of $112.00 to a high of $170.00, representing a 41% spread in expectations. The median target of $141.00 aligns closely with the consensus average.
The current analyst consensus rating is Hold, with 6 analysts rating the stock as a Buy or Strong Buy,17 rating it Hold, and 2 rating it Sell or Strong Sell. The bearish sentiment suggests caution about the stock at current levels.
From a valuation perspective, NVS trades at a trailing P/E of 20.6x and forward P/E of 16.9x. The forward PEG ratio of 1.10 indicates reasonable valuation for growth. Analysts expect EPS to grow +24.1% over the next year.
Our proprietary valuation model, which blends historical multiples with forward estimates, suggests a base-case price target of $168.01, with bear and bull scenarios of $126.95 and $325.75 respectively. Model confidence stands at 56/100, reflecting moderate uncertainty in projections.
Investment Context: Price targets represent analyst expectations for the next 12 months and should be considered alongside your own research. Targets are based on analysts' assumptions about earnings growth, margins, and market conditions which may change. For sector-specific context, view other Healthcare stocks.
Analyst Sentiment Comparison
Industry Peer AnalysisAvg Peer Upside+16.3%
Avg Forward P/E14.0x
Peers with Coverage10 / 10
| Company | Market Cap | Price | Target | Upside | Rating | Fwd P/E | Analysts |
|---|---|---|---|---|---|---|---|
 PFEPfizer Inc. | $150.8B | $26.50 | $27.27 | +2.9% | Hold | 9.0x | 39 |
 AZNAstraZeneca PLC | $286.7B | $184.92 | $211.00 | +14.1% | Buy | 18.0x | 41 |
 NVONovo Nordisk A/S | $203.4B | $45.76 | $47.00 | +2.7% | Buy | 2.1x | 39 |
 SNYSanofi | $105.7B | $43.77 | $50.00 | +14.2% | Buy | 10.4x | 27 |
 GSKGSK plc | $101.6B | $50.53 | $52.45 | +3.8% | Hold | 10.4x | 29 |
 MRKMerck & Co., Inc. | $280.5B | $113.56 | $129.31 | +13.9% | Buy | 22.2x | 37 |
 LLYEli Lilly and Company | $932.6B | $987.11 | $1258.47 | +27.5% | Buy | 28.6x | 45 |
 ABTAbbott Laboratories | $150.0B | $86.25 | $128.71 | +49.2% | Buy | 15.7x | 41 |
 BMYBristol-Myers Squibb Company | $115.4B | $56.54 | $62.00 | +9.7% | Hold | 9.0x | 41 |
 ABBVAbbVie Inc. | $362.6B | $204.98 | $256.64 | +25.2% | Buy | 14.4x | 41 |
Upside Potential Comparison
ABTLLYABBVSNYAZNMRKBMYGSKFull NVS Stock Analysis
Analyst consensus, bull case, AI-generated risk factors, and peer comparison — all in one place.
Should I Buy NVS Right Now?
Bull case, key risks, Wall St analyst verdict, and what council investors are saying — updated daily.
See NVS's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs NVS Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare NVS vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonNVS — Frequently Asked Questions
Quick answers to the most common questions about buying NVS stock.
What is the NVS stock price target for 2026?
Wall Street's consensus price target for NVS is $141, -5.0% from its current price of $148.36. The below-market target from 25 analysts suggests limited near-term appreciation.
Is NVS a buy, sell, or hold?
NVS has a consensus rating of "Hold" based on 25 Wall Street analysts. The rating breakdown is mixed, with 17 Hold ratings making up the largest segment. The consensus 12-month price target of $141 implies -5.0% downside from current levels.
Is NVS stock overvalued or undervalued?
With a forward P/E of 16.9212x, NVS trades at a relatively low valuation. The consensus target of $141 implies -5.0% move, suggesting the market may be pricing in risks.
How high can NVS stock go?
The most bullish Wall Street analyst has a price target of $170 for NVS, while the most conservative target is $112. The consensus of $141 represents the median expectation. Our quantitative valuation model projects a bull case target of $326 based on optimistic growth and margin assumptions. These targets typically reflect 12-month expectations.
How many analysts cover NVS stock?
NVS is heavily covered by Wall Street, with 25 analysts providing price targets and ratings. Of these, 0 have Strong Buy ratings, 6 have Buy ratings, 17 recommend Hold, and 2 have Sell or Strong Sell ratings. Higher analyst coverage generally indicates greater institutional interest and more reliable consensus estimates.
What is the NVS stock forecast?
The 12-month NVS stock forecast based on 25 Wall Street analysts shows a consensus price target of $141, with estimates ranging from $112 (bear case) to $170 (bull case). The median consensus rating is "Hold". Our proprietary valuation model produces a base case fair value of $168, with bear/bull scenarios of $127/$326.
What is NVS's fair value based on fundamentals?
Our quantitative valuation model calculates NVS's fair value at $168 (base case), with a bear case of $127 and bull case of $326. The model uses discounted cash flow analysis, historical growth rates, and margin mean-reversion to project FY+2 earnings, then applies an appropriate P/E multiple. The model confidence score is 56/100.
What is NVS's forward P/E ratio?
NVS trades at a forward P/E ratio of 16.9x based on next-twelve-months earnings estimates compared to a trailing P/E of 20.6x. The lower forward P/E indicates analysts expect earnings growth. A forward P/E is useful for comparing valuations when earnings are expected to change significantly.
Should I buy NVS stock?
Analysts are cautious on NVS, with 2 Sell ratings and a price target of $141 (-5.0% from current price). The "Hold" consensus suggests careful evaluation before buying. This information is for educational purposes only. Always conduct your own research, consider your financial situation, and consult a financial advisor before making investment decisions.
Why do NVS price targets vary so much?
NVS analyst price targets range from $112 to $170, a 41% moderate spread showing some variance in outlooks. Differences stem from varying assumptions about revenue growth, profit margins, competitive dynamics, and valuation multiples. The $141 consensus represents the middle ground. Our model's $127-$326 range provides an independent fundamental perspective.